Peter Gennemark
Adjunct Associate Professor, Docent
My research aims to improve understanding of diabetes and cardiovascular disease and their treatment, by mathematical modelling.
Systems pharmacology – a pharma industry collaboration
Peter Gennemark (Principal scientist at AstraZeneca, Gothenburg, Sweden) is adjunct senior lecturer at IMT. Peter has an established collaboration in systems pharmacology with Gunnar Cedersund (IMT). His research is directed towards systems pharmacology in the diabetes and cardiovascular disease areas, with the aim of increasing knowledge of biology, disease progression and drug intervention in these areas.
Publications
2026
Systemic Pharmacokinetic Principles of Therapeutic Peptides
Clinical Pharmacokinetics, Vol. 65, p. 571-582
(Article in journal)
https://dx.doi.org/10.1007/s40262-025-01615-z
2025
Multimeric Conjugates Using Engineered Peptide Scaffolds for Efficient siRNA Delivery
Bioconjugate chemistry, Vol. 36, p. 1299-1310
(Article in journal)
https://dx.doi.org/10.1021/acs.bioconjchem.5c00156
2024
Tissue pharmacokinetics of antisense oligonucleotides
Molecular Therapy - Nucleic Acids, Vol. 35, p. 102133-102133, Article 102133
(Article in journal)
https://dx.doi.org/10.1016/j.omtn.2024.102133
3D cell aggregates amplify diffusion signals
PLOS ONE, Vol. 19, Article e0310109
(Article in journal)
https://dx.doi.org/10.1371/journal.pone.0310109
Normoglycemia and physiological cortisone level maintain glucose homeostasis in a pancreas-liver microphysiological system
Communications Biology, Vol. 7, Article 877
(Article in journal)
https://dx.doi.org/10.1038/s42003-024-06514-w